ORKA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

OR

Mkt Cap

$4.76B

Volume

1.18M

Next Earnings

November 11th

Loading chart

OR

ORKAOruka Therapeutics, Inc. Common Stock

ORKA

Pay with—

Available Balance0.00

OR

Mkt Cap

$4.89B

Volume

1.18M

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside AheadRevolution Medicines and Oruka Therapeutics have significantly outperformed the Magnificent Seven tech stocks this year, both more than doubling. Revolution Medicines gained FDA approval for Rasonque, a pancreatic cancer treatment with blockbuster potential ($20.8B peak revenue projected). Oruka Therapeutics is developing ORKA-001 for psoriasis with promising Phase 2 results and convenient once-yearly dosing. While Wall Street sees substantial upside (36% for RVMD, 95% for ORKA), both stocks carry significant risk due to clinical uncertainty and limited approval history.The Motley Fool · Oct 15, 2026

Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional DosingOruka Therapeutics reported positive Week 28 interim data from its EVERLAST-A Phase 2a trial of ORKA-001, an IL-23p19 monoclonal antibody for plaque psoriasis. The drug demonstrated deepening clinical responses with 71.4% of patients achieving PASI 100 (complete skin clearance) and 87.3% achieving PASI 90, six months after the last dose with no additional dosing beyond Week 4. The drug maintained a favorable safety profile consistent with the IL-23 class. Full 52-week data is expected in December 2026.GlobeNewswire Inc. · Sep 23, 2026

Oruka Therapeutics Appoints Todd Edwards as Chief Commercial OfficerOruka Therapeutics announced the appointment of Todd Edwards as Chief Commercial Officer effective August 24, 2026. Edwards brings over 25 years of commercial leadership experience in immunology and dermatology from previous roles at Arcutis Biotherapeutics, Incyte Corporation, UCB S.A., and AbbVie. The appointment reflects Oruka's commitment to building a commercial organization to advance its pipeline candidates ORKA-001 and ORKA-002 toward commercialization for chronic skin diseases.GlobeNewswire Inc. · Aug 24, 2026

Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could MeanOruka Therapeutics' Senior Vice President of Finance Arjun Agarwal sold 9,854 shares worth approximately $687,000 in mid-June 2026, reducing his direct holdings by 36.83%. The sale occurred after the stock had already surged 450% over the previous year and two weeks before it reached nearly 700% gains. The insider sale follows positive Phase 2 clinical data for the company's monoclonal antibody therapies ORKA-001 and ORKA-002, though the company continues to operate at a net loss with quarterly losses widening to $31.8 million.The Motley Fool · Jun 27, 2026

Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, sold 10,290 shares worth approximately $608,000 on May 18, 2026, at a weighted average price of $59.07 per share. The sale was part of a pre-arranged Rule 10b5-1 trading plan and should not concern investors, as it was non-discretionary. The transaction came after the stock surged 457.71% over one year, driven by encouraging clinical trial data and a $700 million public offering announced in April.The Motley Fool · Jun 24, 2026

An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 MillionCarl Dambkowski, Director of Oruka Therapeutics, sold 105,000 shares worth approximately $6.19 million on May 21, 2026, reducing his direct holdings by 58.74%. Despite the significant sale, Dambkowski retains approximately 73,743 shares and derivative securities. The sale was executed through the exercise and immediate sale of vested options. Oruka, a clinical-stage biotech company developing monoclonal antibody therapeutics, has seen its stock surge 407% over the past 12 months following positive clinical trial results for its lead candidate ORKA-001 in psoriasis treatment.The Motley Fool · May 31, 2026

A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?Oruka Therapeutics reported strong phase 2a trial results for ORKA-001, showing 63.5% PASI 100 response rates compared to Skyrizi's typical 51%, potentially threatening AbbVie's $17.6 billion psoriasis drug. However, the article argues AbbVie remains a solid long-term investment due to its diverse pipeline, other growth drivers like Qulipta and Botox, and its status as a Dividend King.The Motley Fool · May 11, 2026

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public OfferingOruka Therapeutics priced an upsized underwritten public offering of 9.66 million shares at $72.50 per share, generating approximately $700.4 million in gross proceeds. The offering is expected to close on or about April 30, 2026, with underwriters granted a 30-day option to purchase up to 1.45 million additional shares.GlobeNewswire Inc. · Apr 28, 2026

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public OfferingOruka Therapeutics (NASDAQ: ORKA), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for psoriasis and inflammatory conditions, announced a proposed $500 million underwritten public offering of common stock and pre-funded warrants. The company also expects to grant underwriters a 30-day option to purchase an additional $75 million in shares. The offering is subject to market conditions and SEC approval.Benzinga · Apr 27, 2026

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightOver 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.GlobeNewswire Inc. · Apr 14, 2026

to start trading

OR

ORKAOruka Therapeutics, Inc. Common Stock

ORKA

Pay with—

Available Balance0.00

Your PositionYou don't own any ORKA yet.

Related Tickers

Earnings